The ABO blood group system, which consists of three main alleles (two codominant A and B and one recessive O), is controlled by a single gene located on the terminal portion of the long arm of chromosome 9 (9q34.2).
1,2 The A and B alleles encode slightly different glycosyltransferases (transferase A, α 1-3-N-acetylgalactosaminyltransferase; transferase B, α 1-3-galactosyltransferase) that add N-acetylgalactosamine and D-galactose, respectively, to a common precursor side chain, the H substance, converting it into A or B antigens. The O allele does not encode a functional enzyme and consequently OO carriers, who lack these transferase enzymes, continue to express the basic, unmodified H structure constituting a solitary terminal fucose moiety attached to the precursor oligosaccharide chain.
3
Besides their presence on red blood cells, ABO antigens are also expressed on the surface of a variety of human cells and tissues, including epithelial cells, sensory neurons, platelets, and the vascular endothelium. 4 It is, therefore, plausible from a biological point of view that the clinical significance of ABO blood type may not be limited only to transfusion medicine; indeed, there is a large amount of data from the literature consistently documenting the involvement of ABO blood group antigens in the development of a wide array of human diseases. [5] [6] [7] [8] [9] [10] [11] [12] [13] This narrative review will summarize the main biologic and clinical evidence of the interaction between hemostasis and ABO blood type focusing on its role in clinical scoring systems assessing thrombotic risk.
ABO Blood Type and Thrombosis
As previously mentioned, several studies have reported over the past 50 years the primary relation of ABO blood type with thrombosis, [14] [15] [16] [17] [18] [19] [20] [21] [22] and the recent discovery of the ABO gene as the most involved locus for both primary and recurrent venous thromboembolism (VTE) and arterial thrombosis (i.e., myocardial infarction, coronary artery disease, and ischemic stroke) has further corroborated this
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Abstract
In addition to their major role in transfusion medicine, there is increasing evidence that ABO blood group antigens (complex carbohydrate molecules widely expressed on the surface of red blood cells and several other cell types) are implicated in the development of a wide array of pathologic conditions. In particular, intense research has been dedicated over the last 50 years to the study of the association between non-O blood type and the risk of developing cardiovascular disorders. Several pathways have been hypothesized to explain this relationship, the most reasonable implying the influence of the ABO blood group on circulating plasma levels of von Willebrand factor, factor VIII, and several inflammatory cytokines. This narrative review summarizes the current knowledge on the role of ABO antigens in both venous and arterial thromboses, focusing on their association with clinical scoring systems evaluating thrombotic risk.
hypothesis. [23] [24] [25] [26] Several systematic reviews and meta-anal- 33 Notably, the authors identified the rs579459 variant (which tags the A1 allele) in the ABO locus as having the fifth highest association, with an OR of 1.10 (95% CI, 1.07-1.13). The profound influence exerted on hemostasis by ABO antigens, demonstrated by their close relationship with von Willebrand factor (VWF) and, consequently, coagulation factor VIII (FVIII) plasma levels, has been proposed to explain the association between ABO blood group and thrombotic vascular disease. 34 Indeed, while it has been established that the ABO system is responsible for approximately 15 and 10% of overall VWF and FVIII interindividual variability, respectively, 35, 36 it is equally well known that subjects with non-O blood group have VWF and FVIII circulating levels that are approximately 25% higher than O blood group subjects. 33 The presence of ABO blood group determinants on VWF N-glycans provides the molecular basis of the connection between ABO blood group and VWF levels. 34 In individuals
with O blood group, VWF is cleaved by ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) and undergoes enhanced clearance through low-density lipoprotein receptor-related protein 1 (LRP1), resulting in a reduced VWF activity compared with those with non-O blood group. Conversely, in individuals with non-O blood group, the A/B/AB antigen-related VWF glycosylation protects it from proteolysis and clearance by ADAMTS13 and LRP1, respectively, resulting in increased VWF levels compared with those with O blood group.
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Beyond the association with levels of circulating VWF, recent investigations have been focused on the capacity of ABO blood group antigens to influence serum levels of several inflammatory cytokines (i.e., tumor necrosis factor-α, soluble intercellular adhesion molecule 1, E-selectin, P-selectin, and interleukin 6), whose higher concentrations have been associated with an increased risk of cardiovascular thrombotic events. [40] [41] [42] [43] Finally, the observations of the association between the ABO locus and plasma lipoprotein concentrations 44 and between non-O blood types and increased circulating cholesterol levels 45, 46 add another important contribution to the understanding of the pathogenic mechanisms underlying the correlation between ABO blood group and coronary heart disease susceptibility. All in all, these data document that the relation between the ABO blood group system and cardiovascular diseases is more complex than the simple modulation of hemostasis.
Interaction between ABO Blood Type and Other Thrombotic Risk Factors
Besides the consistent experimental and clinical observations of the close relationship between ABO blood group and thrombotic vascular disease, several studies have also investigated the interaction between ABO antigens and other known thrombotic risk factors. 
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The main results of the most important studies assessing the link between ABO blood type and inherited and/or acquired thrombotic conditions are summarized in ►Table 1.
ABO Blood Type and Cardiovascular Scoring Systems
As previously described, there is a large body of evidence consistently demonstrating that ABO blood type is not only an important genetic determinant of venous and arterial thromboses but it is also able to interact with other genetic and nongenetic factors in the modulation of thrombotic risk. As a result, with the aim of better quantifying the ABO attributable thrombotic risk, some investigators have assessed the association of ABO blood group with scores evaluating arterial thrombotic risk. Yang et al 58 investigated
ABO blood group in 1,311 young Chinese adults with acute ischemic cerebral stroke by using the National Institutes of Health Stroke Scale (NIHSS) score, a valid, reliable, and reproducible neurological severity scale performed at admission and associated with chronic functional outcome. Notably, the authors demonstrated the utility of the score as a predictor of clinical outcomes in ABO blood group, since stroke patients with non-O blood group have a higher probability of an unfavorable outcome at discharge than O blood type patients with the same NIHSS scores. In addition, Gong et al 59 investigated the relation of ABO blood type and the severity of coronary atherosclerosis assessed by the Gensini score, a useful angiographic system to assess fatal and nonfatal cardiovascular events. The results of this large Chinese cohort study, which enrolled 2,919 consecutive patients undergoing coronary angiography, showed that while blood group A was an independent risk factor (OR, 1.44; 95% CI, 1.16-1.80; p ¼ 0.001), group O was a protective factor (OR, 0.77; 95% CI, 0.65-0.92; p ¼ 0.004) for serious coronary atherosclerosis. Finally, the relationship 
Conclusion
Overall, a large body of evidence from experimental and clinical studies documents the close link between the ABO blood group system and hemostasis, and several lines of research indicate that ABO blood group antigens might modulate various distinct pathways related to cardiovascular risk factors, atherosclerosis, and thrombosis. Thanks to intense research in this field, today, it is possible to conclude that non-O blood type is an independent risk factor for both venous and arterial thromboses. In addition, investigation of the association between ABO antigens and traditional cardiovascular risk factors in the context of thrombotic score assessments has identified non-O blood type as an important cardiovascular prognostic biomarker. However, research in this field is in its early stages and further studies are needed to better clarify the interaction of the ABO antigens with other acquired and inherited thrombotic risk factors. In particular, considering that non-O blood type is associated with an approximately twofold increased VTE risk, it could be very interesting to analyze its relation with scores assessing the risk of primary and recurrent vein thrombosis.
